Core Insights - NuCana plc presented data at the European Society for Medical Oncology Congress 2025, demonstrating the synergistic effects of NUC-7738 in combination with PD-1 inhibitors in renal cell carcinoma [1][2] - The data reinforces the mechanism of action of NUC-7738, showing a favorable safety profile and significant tumor volume reduction in patients resistant to PD-1 inhibitors [3] Company Overview - NuCana is a clinical-stage biopharmaceutical company focused on improving cancer treatment outcomes through its ProTide technology, which transforms nucleoside analogs into more effective and safer medicines [5][6] - The company's pipeline includes NUC-7738, which disrupts RNA polyadenylation and targets multiple aspects of the tumor microenvironment, and NUC-3373, derived from 5-fluorouracil [6] Clinical Study Updates - The ongoing Phase 1/2 NuTide:701 clinical study is evaluating NUC-7738 as a monotherapy and in combination with pembrolizumab for melanoma patients, with an expansion to recruit an additional 28 patients approved by regulators [4][6] - Initial data from the NuTide:701 study indicates that NUC-7738 may sensitize various cancers to PD-1 inhibitor therapy, enhancing treatment options for patients [4][6]

Core Insights - NuCana plc announced new data on NUC-3373, showing favorable efficacy and safety in heavily pre-treated patients with advanced solid tumors, particularly in combination with pembrolizumab [1][2] - The latest data indicates a patient with metastatic melanoma remains progression-free at 23 months, demonstrating a durable partial response [1][4] - Preclinical data supports the immunogenic effects of NUC-3373, enhancing immune cell activation and tumor cell death [2][4] Company Overview - NuCana is a clinical-stage biopharmaceutical company focused on improving cancer treatment outcomes through its ProTide technology, which transforms conventional chemotherapy agents into more effective and safer medicines [3] - The company's pipeline includes NUC-7738 and NUC-3373, with NUC-3373 being evaluated in a Phase 1b/2 modular study in combination with pembrolizumab for advanced solid tumors [5] Clinical Study Findings - In the NuTide:303 study, NUC-3373 combined with pembrolizumab showed a 100% reduction in tumor lesion size in a patient with urothelial carcinoma and an 81% reduction in target lesions in a patient with metastatic melanoma resistant to prior therapy [4] - The combination therapy is noted for its favorable safety profile and evidence of durable disease control [2][4] Future Directions - The company is exploring optimal combinations and indications for further clinical studies of NUC-3373 while maintaining a cash runway into 2029 [2]

Group 1: Penguin Solutions, Inc. - Penguin Solutions reported fourth-quarter earnings of 43 cents per share, exceeding the analyst consensus estimate of 38 cents per share [1] - The company reported quarterly sales of $337.922 million, which fell short of the analyst consensus estimate of $342.112 million [1] - For FY2026, Penguin Solutions projects adjusted earnings between $1.75 to $2.25 per share and sales ranging from $1.314 billion to $1.588 billion [2] - Following the earnings report, shares of Penguin Solutions dipped 17.6% to $22.24 in pre-market trading [2] Group 2: Other Companies - Esperion Therapeutics, Inc. saw a decline of 20.1% to $2.47 after announcing a public offering of common stock [4] - NOVONIX Limited experienced a drop of 12.7% to $1.79 after a previous increase of 14% [4] - NANO Nuclear Energy Inc. fell 9.1% to $51.50 following a $400 million oversubscribed private placement of common stock [4] - Joby Aviation, Inc. decreased by 8.5% to $17.30 after pricing a $513.9 million underwritten offering of common shares [4] - Archer Aviation Inc. declined 4.1% to $11.95 after a previous drop of more than 8% [4] - NextNRG Inc. fell 3.2% to $2.73 after a significant increase of 36% the previous day [4] - NuCana plc decreased by 3% to $6.81 in pre-market trading [4]

Core Viewpoint - NuCana plc has confirmed compliance with Nasdaq's continued listing criteria, closing a previously disclosed listing matter, and is well-positioned for future operations and clinical milestones [1][2]. Company Overview - NuCana is a clinical-stage biopharmaceutical company focused on improving cancer treatment outcomes through its ProTide technology, which enhances the efficacy and safety of widely prescribed chemotherapy agents [3]. - The company's pipeline includes NUC-7738, currently in Phase 2 trials for advanced solid tumors and melanoma, and NUC-3373, being evaluated in a Phase 1b/2 study for advanced solid tumors and lung cancer [3]. Financial Position - The company anticipates that its existing cash resources, bolstered by proceeds from an ATM offering, will be sufficient to fund operations into 2029 [2].

Core Points - NuCana plc will present at the ESMO Congress 2025, focusing on the synergy between NUC-7738 and PD-1 inhibition in renal cell cancer [1] - The presentation is scheduled for October 19, 2025, and will be part of the Investigational Immunotherapy session [1] - NuCana is a clinical-stage biopharmaceutical company utilizing ProTide technology to enhance chemotherapy agents [3] Company Overview - NuCana aims to improve cancer treatment outcomes by transforming nucleoside analogs into more effective and safer medicines [3] - The company's pipeline includes NUC-7738, which is in Phase 2 of a Phase 1/2 study, and NUC-3373, currently in a Phase 1b/2 modular study [3] - NUC-7738 targets multiple aspects of the tumor microenvironment and disrupts RNA polyadenylation [3]

Exhibit 99.1 NUCANA PLC UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS | | | For the Three Months Ended | | For the Six Months Ended | | | --- | --- | --- | --- | --- | --- | | | | June 30, | | June 30, | | | | Notes | 2025 | 2024 | 2025 | 2024 | | | | | (in thousands, except per share data) | | | | | | £ | £ | £ | £ | | Research and development expenses | | (7,104) | (6,769) | (8,829) | (13,552) | | Administrative expenses | | (4,523) | (1,509) | (5,590) | (3,090) | | Net foreign exchange (losse ...

Core Insights - NuCana plc has initiated the dosing of the first patients in the expansion study of NUC-7738 in combination with pembrolizumab for patients with PD-1 inhibitor-resistant melanoma, with initial data expected in Q4 2025 and final data in 2026 [1][2] - The company reported a net loss of £24.1 million for Q2 2025, which includes a significant loss on revaluation of warrants, compared to a net loss of £7.0 million in Q2 2024 [7][11] - NuCana's cash and cash equivalents increased to £8.4 million as of June 30, 2025, up from £4.0 million at the end of Q1 2025, with additional funds raised through an ATM offering expected to extend the cash runway into 2029 [4][6] Clinical Development - NUC-7738 is designed to impact gene expression in cancer cells and has shown a favorable safety profile, meaningful tumor volume reduction, and prolonged progression-free survival in patients with PD-1 inhibitor refractory metastatic melanoma [2] - NUC-3373, another lead program, is a targeted thymidylate synthase inhibitor with immune-modulating properties, currently in a Phase 1b/2 study, showing notable tumor volume reductions and prolonged progression-free survival in patients with advanced solid tumors [2][5] Financial Position - As of June 30, 2025, NuCana's total assets were £16.2 million, with total equity attributable to equity holders amounting to £7.4 million [12][13] - The company has raised gross proceeds of £38.4 million in 2025 through various financing initiatives, positioning it well for upcoming clinical milestones [2][6] Anticipated Milestones - Initial data from the Phase 1/2 expansion study of NUC-7738 is expected in 2025, with regulatory guidance from the FDA anticipated in 2026 [5] - Additional data from the ongoing Phase 1b/2 study of NUC-3373 is also expected to be announced later in 2025 [5]

Core Points - NuCana plc will change the ratio of its American Depository Shares (ADSs) from one ADS representing twenty-five ordinary shares to one ADS representing five thousand ordinary shares, effective August 11, 2025 [1][2] - This change is equivalent to a one-for-two hundred reverse ADS split and aims to support liquidity and regain compliance with Nasdaq's minimum bid price requirement [2][3] - The exchange will occur automatically for holders of uncertificated ADSs, while certificated holders must surrender their ADSs for cancellation [2] - The change will not affect shareholders' proportional equity interests, except for fractional ADSs, which will be aggregated and sold [2] - The trading price of ADSs is expected to increase proportionally, although no assurance can be given regarding the actual trading price post-change [3] Company Overview - NuCana is a clinical-stage biopharmaceutical company focused on improving cancer treatment outcomes through its ProTide technology [4] - The company is developing new medicines, ProTides, to enhance the efficacy and safety of conventional chemotherapy agents [4] - NuCana's pipeline includes NUC-7738, currently in Phase 2 studies for advanced solid tumors, and NUC-3373, being evaluated in a Phase 1b/2 study for advanced solid tumors and lung cancer [4]

Core Viewpoint - NuCana plc has successfully canceled all remaining Series A Warrants, raising the necessary capital through its at-the-market offering, thereby eliminating overhanging rights from its May 2025 registered direct offering [1][2]. Company Overview - NuCana is a clinical-stage biopharmaceutical company focused on improving cancer treatment outcomes using its ProTide technology to enhance the efficacy and safety of widely prescribed chemotherapy agents [3]. - The company's pipeline includes NUC-7738, a novel anti-cancer agent in Phase 2 studies, and NUC-3373, currently in a Phase 1b/2 modular study, both targeting advanced solid tumors [3].

Core Viewpoint - NuCana plc plans to change the ratio of its American Depository Shares (ADSs) from 1 ADS representing 25 ordinary shares to 1 ADS representing 5,000 ordinary shares, effective around August 8, 2025, to support liquidity and regain compliance with Nasdaq's minimum bid price requirement [1][2]. Company Overview - NuCana is a clinical-stage biopharmaceutical company focused on improving cancer treatment outcomes through its ProTide technology, which aims to enhance the efficacy and safety of widely prescribed chemotherapy agents [4]. - The company's pipeline includes NUC-7738, a novel anti-cancer agent in Phase 2 studies, and NUC-3373, currently in a Phase 1b/2 modular study, both targeting advanced solid tumors [4]. ADS Ratio Change Details - The change in the ADS Ratio will effectively act as a one-for-two hundred reverse ADS split, with no impact on the proportional equity interest of ADS holders [2]. - Registered holders of certificated ADSs must surrender their existing ADSs for cancellation to receive new ADSs, while holders of uncertificated ADSs will have their ADSs automatically exchanged [2]. - No fractional new ADSs will be issued; instead, fractional entitlements will be aggregated and sold, with net cash proceeds distributed to ADS holders [2]. Expected Impact - The trading price of ADSs is expected to increase proportionally due to the change in the ADS Ratio, although the company cannot guarantee that the new trading price will be equal to or greater than the previous price [3].